Jurkat cells express Fas, and rapidly undergo apoptosis in response to Fas ligand or an agonistic anti-Fas antibody. This apoptotic pathway is mediated by a cascade of caspases. In this report, we show that Fas activation induced the processing of caspase 8 in Jurkat cells with a time frame similar to the activation of caspase 3 and the proteolysis of nuclear proteins. Jurkat cell transformants that overexpress Bcl-2 were partially but not completely resistant to the Fas-induced apoptosis. Little processing of caspase 8 was observed upon Fas activation in these transformants. Furthermore, although caspase 8 was recruited to Fas upon Fas activation in the parental Jurkat cells, the recruitment of caspase 8 to Fas was inhibited in the transformants overexpressing Bcl-2. These results suggest that Bcl-2 inhibits Fas-induced apoptosis by preventing the formation of the deathinducing signaling complex that is composed of Fas, FADD/MORT1, and caspase 8.
Introduction
Apoptosis is an innate cell suicide mechanism that abates unwanted, harmful, and neoplastic cells (Jacobson et al., 1997) . Various stimuli, including cytokines, anti-cancer drugs, and UV-or g-irradiation trigger the apoptotic program , which is characterized morphologically by condensation and fragmentation of cells and nuclei, and biochemically by fragmentation of the chromosomal DNA (Wyllie et al., 1980) . Regardless of the stimuli, apoptotic signals ultimately lead to the same biochemical events downstream in the signaling cascade. That is, all apoptotic stimuli activate members of the caspase family, which cleave various cellular substrates, leading to morphological changes in the cells as well as to the fragmentation of chromosomal DNA (Chinnaiyan and Dixit, 1996; Enari et al., 1998; Nicholson and Thornberry, 1997; Sakahira et al., 1998) .
Fas (also called APO-1 or CD95), a receptor for Fas ligand (FasL), belongs to the tumor necrosis factor (TNF) receptor family, and transduces the apoptotic signal into cells (Nagata and Golstein, 1995) . The molecular mechanism for Fas-induced apoptosis is currently being elucidated. Aggregation of the Fas receptor by the binding of FasL to Fas, or by crosslinking with an agonistic anti-Fas antibody induces the formation of a death-inducing signaling complex (DISC) of proteins composed of Fas, an adaptor called FADD/MORT1, and the inactive proform of caspase 8 (Kischkel et al., 1995) . Oligomerization of procaspase 8 in the DISC seems to induce its selfprocessing into the mature, active protease, containing p20 and p10 subunits. The activated caspase 8 is then released from the DISC, and activates other downstream caspases by proteolytic cleavage of their zymogen forms .
In many cells, overexpression of anti-apoptotic members of the Bcl-2 gene family, such as Bcl-2 and Bcl-X L , inhibits the apoptosis induced by a variety of stimuli (Cory, 1995; Korsmeyer, 1995; Reed, 1997) . Bcl-2 and Bcl-X L localize in cells to the cytoplasmic membranes of mitochondria, endoplasmic reticulum, and nuclei. Despite extensive studies, the molecular mechanism by which Bcl-2 and Bcl-X L inhibits apoptosis is still not clearly understood. Fas-induced apoptosis is also inhibited by Bcl-2 and Bcl-X L in variety of cells (Boise and Itoh et al., 1993; JaÈ aÈ ttelaÈ et al., 1995; Rodriguez et al., 1996) , although perhaps not in all Fas-expressing cells (Memon et al., 1995; Strasser et al., 1995) . Since the signaling pathway for Fas-induced apoptosis is rather well characterized, we investigated the eect of Bcl-2 on each step of this process. In this report, we show that overexpression of Bcl-2 in human Jurkat cells partially inhibits the cell death triggered by Fas activation. The cleavage of cellular substrates such as poly(ADP-ribose) polymerase (PARP) and lamins occurred signi®cantly more slowly in transformants overexpressing Bcl-2 than in the parental Jurkat cells. Similarly, the Fas-induced processing of procaspases 3 and 8 was retarded in Bcl-2-overexpressing cells. Finally, the FasL-induced DISC formation was inecient in Bcl-2-overexpressing cells. These results suggest that the partial inhibition of Fas-induced apoptosis by Bcl-2 is due at least in part, to the inhibition of the recruitment of procaspase 8 to the Fas receptor.
Results

Inhibition of Fas-induced apoptosis by Bcl-2
We have previously shown that overexpression of Bcl-2 partially inhibits Fas-induced apoptosis in mouse WR19L cells in vitro and mouse hepatocytes in vivo (Itoh et al., 1993; Rodriguez et al., 1996) . To examine whether Bcl-2 inhibits Fas-induced apoptosis in other cell types, we established Jurkat cell transformants that overexpress human Bcl-2. As shown in Figure 1a , the parental Jurkat cells expressed only very low levels of Bcl-2, whereas both independent transformant clones (JB-2 and JB-3) expressed similar high levels of Bcl-2. Jurkat cells endogenously express Fas on their surface, and Fas expression was not aected by Figure 1c , half of the Jurkat cells died within 12 h with 3 ng/ml of the anti-Fas antibody. On the other hand, 40 ng/ml of the antiFas antibody was necessary to kill the Bcl-2 transformants, and more than 40% of the cells remained alive even when they were incubated for 12 h with 0.3 mg/ml of the antibody. These results indicated that Bcl-2 has a potent inhibitory eect on Fas-induced apoptosis in human Jurkat cells.
Inhibition of the Fas-induced processing of caspase 8 by Bcl-2
The engagement of Fas with its ligand leads to the activation of a cascade of caspases (Fraser and Evan, 1996; . Caspases exist as precursor forms in growing cells. When cells are activated to apoptosis, the precursor forms of caspases undergo proteolytic processing to mature forms (Nicholson and Thornberry, 1997). Among these, caspase 8 appears to be the ®rst protease that is activated, and this activation occurs in the DISC consisting of Fas, the adaptor molecule FADD/MORT1, and procaspase 8 (Kischkel et al., 1995) . To examine whether caspase 8 is actually activated by the Fas engagement, a monoclonal antibody against human caspase 8 was developed, and used for Western blotting analysis. As shown in Figure 2 , human procaspase 8 was detected as a doublet at 54 and 55 kDa, which agrees with the recent report that two dierent forms of human procaspase 8 are produced from two alternatively spliced mRNAs . When Jurkat cells were treated with the anti-Fas antibody, procaspase 8 was quickly processed to the mature p18 protein through its intermediate p43, as reported previously . The time course for the processing of procaspase 8 was similar to that for procaspase 3 as well as for the cleavage of PARP and lamin B1. We then examined the eect of Bcl-2 on the processing of procaspases 8 and 3, the cleavage of PARP, lamin B1, and DNA fragmentation. The Jurkat cell transformant clones (JB-2 and JB-3) that overexpress Bcl-2 expressed procaspase 8 at a level similar to the parental Jurkat cells (Figure 3a ). When these cells were treated with the anti-Fas antibody, the cleavage of procaspase 8 was signi®cantly retarded as compared with that observed in the parental Jurkat cells. Most of the proform of caspase 8 disappeared during a 2 h incubation with the anti-Fas antibody in the parental Jurkat cells (Figure 2 ). In contrast, half of the caspase 8 proform remained intact after a 4 h treatment with the anti-Fas antibody in JB-2 and JB-3 cells (Figure 3a) . Similarly, the processing of procaspase 3, the cleavage of PARP and lamin B1, and the fragmentation of chromosomal DNA were retarded in JB-2 and JB-3 cells (Figure 3a and b) . These results indicated that the partial resistance of the Bcl-2-overexpressing cells to Fas-induced apoptosis was due in part to a defect in the processing of procaspase 8.
Inhibition of Fas-induced recruitment of procaspase 8 to Fas by Bcl-2
Processing of procaspase 8 occurs at the plasma membrane, where it is recruited to the Fas cytoplasmic region via an adaptor, FADD/MORT1 . To examine the mechanism for the defect in procaspase 8 processing in the cells overexpressing Bcl-2, Jurkat cells and JB-3 cells were treated for 5 min with the soluble FasL at a concentration sucient to kill about 80% of the Jurkat cells within 12 h. The procaspase 8 was immunoprecipitated with the anticaspase 8 antibody, and analysed by Western blotting, probing with rabbit anti-Fas antibody. As shown in Figure 4 , the Fas protein could be detected in the immunoprecipitates from the Jurkat cells treated with FasL, but not in the immunoprecipitates from the untreated Jurkat cells, indicating that procaspase 8 quickly associated with Fas upon Fas engagement. In contrast, the amount of procaspase 8 associated with Fas in JB-3 cells was very low after a 5 min treatment with soluble FasL. On the other hand, when the association of caspase 8 with Fas was examined after a 30 min treatment with the soluble FasL, less signi®cant dierence was observed between the Jurkat and JB-3 cells (data not shown). These results indicated that Bcl-2 can inhibit or retard the recruitment of procaspase 8 to the Fas receptor.
Discussion
Fas activation induces the recruitment of procaspase 8 to the Fas receptor, and this association triggers the caspase cascade that leads to apoptosis (Kischkel et al., 1995) . In this report, we could detect the rapid FasLinduced association of caspase 8 with Fas in Jurkat cells. On the other hand, Scadi et al. (1998) observed little DISC formation in Jurkat cells, and suggested that a caspase dierent from caspase 8 is activated at the initial stage of the Fas-induced apoptosis, which then damages mitochondria to activate caspase 3 and 8. Since we have not studied the damage of mitochondria during the Fas-induced apoptosis, we cannot rule out this possibility. However, we have recently established a subline of Jurkat cells, which is de®cient in caspase 8. The cell line was completely resistant to the Fas-induced apoptosis, and no caspase 3 activation was observed by the Fas-engagement in this cell line (manuscript in preparation), suggesting that caspase 8 is the primary caspase even in Jurkat cells.
The overexpression of Bcl-2 in human Jurkat cells caused inecient recruitment of procaspase 8 to the Fas receptor. We propose that this mechanism is responsible, at least in part, for the slow processing of procaspases 8 and 3, and for the partial inhibition of Fas-induced apoptosis in Bcl-2-overexpressing cells. These results agree with previous reports indicating that overexpression of Bcl-X L inhibits the activation of caspase 3, thus preventing Fas-induced apoptosis (Armstrong et al., 1996; Mandal et al., 1996) . This mechanism is also consistent with the inecient DISC formation observed in human T cells activated for a short period, which express Bcl-X L and are resistant to Fas-induced apoptosis .
In contrast to our results, Medema et al. (1998) and Srinivasan et al. (1998) indicated that the Fas-induced DISC formation as well as processing of procaspase 8 were not aected by Bcl-X L in human MCF7 breast carcinoma cells that were engineered to overexpress human Fas. These contradictory results are probably due to the dierences in the expression levels of Fas between Jurkat and MCF7 cells. If the inhibition of the DISC formation by Bcl-2 is due to the sequestering of procaspase 8 from the cytosol as discussed below, it is conceivable that the DISC formation is determined by a balance between the signals that recruit procaspase 8 to the Fas receptor and those that act to sequester it. Overexpression of Fas sensitizes cells to Fas-induced apoptosis (Clement and Stamenkovic, 1994) , suggesting that increased clustering of Fas on the plasma membrane results in a stronger ability to recruit procaspase 8, which would overcome the sequestering of procaspase 8 by Bcl-2. Furthermore, it is possible that the expression levels of other signaling molecules such as FADD/MORT1 and caspase 8, relative to that of Bcl-2, could in¯uence the inhibitory function of Bcl-2 or Bcl-X L on Fas-induced apoptosis. For example, if the cells are abundant in procaspase 8, the eect of Bcl-2 on the DISC formation would probably be small. In this regard, it would be necessary to compare the expression levels of Fas, FADD, and procaspase 8. Such analyses might clarify why the overexpression of Bcl-2 is eective in preventing Fas-induced apoptosis in some types of cells, but not in others. How does the overexpression of Bcl-2 inhibit the Fas-induced recruitment of procaspase 8 to the Fas receptor? At least two possible mechanisms have been proposed for the inhibitory function of Bcl-2 in apoptosis. Mitochondria damage induced by apoptotic stimuli is known to cause the release of cytochrome C and/or apoptosis-inducing factor (AIF) to promote the cell-death program (Liu et al., 1996; Susin et al., 1997) . The pore-forming property of Bcl-X L suggests that Bcl-X L prevents mitochondrial damage by enabling it to maintain its membrane potential and volume homeostasis (Heiden et al., 1997) . In the second model, procaspase 8 is sequestered by Bcl-2 in the mitochondria through Ced-4 protein, a cell-death regulator in C. elegans (Chinnaiyan et al., 1997; Spector et al., 1997; Wu et al., 1997) . Although the ability of Apaf-1, the putative mammalian homolog of Ced-4, to bind to Bcl-2 and procaspase 8 has not yet been demonstrated, the latter mechanism provides a likely explanation of the inhibitory activity of Bcl-2 on the DISC formation. Since the activation of procaspase 8 occurs only at the DISC on the plasma membrane, it is possible that the sequestering of procaspase to mitochondria inhibits its recruitment to the DISC, thus slowing down its processing.
Finally, Bcl-2 and Bcl-X L are a multi-functional proteins, and seem to inhibit the apoptotic process at many stages by interacting with various proteins (Reed, 1997) . In this regard, we cannot rule out the possibility that Bcl-2 and Bcl-X L inhibit Fas-induced apoptosis downstream of the signaling cascade, in addition to their inhibitory function on the recruitment of procaspase 8 to the DISC.
Materials and methods
Antibodies and soluble human Fas ligand
To establish a mouse hybridoma producing anti-human caspase 8 antibody, the C-terminal portion of human caspase 8 (amino acids 176 ± 460) was produced in E. coli as a fusion protein with glutathione S-transferase. The fusion protein was used to immunize mice, and a hybridoma (clone 5F7) producing the anti-human caspase 8 antibody was identi®ed. To produce anti-human Fas antibody, the cytoplasmic region of human Fas (amino acids 190 ± 333) was tagged with polyhistidine using the pQE vector (QIAGEN). The protein was produced in E. coli and puri®ed on a QIAexpress Ni-NTA column (QIAGEN). Rabbits were immunized with the puri®ed protein, and the serum was used as the anti-human Fas serum. Mouse monoclonal antibodies against human Fas (clone CH11) and human caspase 3 (clone 19) were purchased from Medical and Biological Laboratories (Nagoya, Japan) and Transduction Laboratories (Lexington, KY, USA), respectively. Mouse monoclonal antibody against human PARP (clone C-2-10) was provided by Dr GG Poirier. Mouse monoclonal antibodies against human lamin B1 (clone 101-B7) and a-tubulin (clone DMIA) were from Oncogene Science Inc. (Cambridge, MA, USA), and the antibody against human Bcl-2 (clone 4D7) was from PharMingen (San Diego, CA, USA). Horseradish (HRP)-conjugated goat anti-mouse and anti-rabbit IgG were obtained from DAKO (Denmark) and Bio-Rad Laboratories (Hercules, CA, USA), respectively. Soluble FasL was prepared by transfecting COS cells with the expression plasmid for mouse FasL (pEF-WX1) as described previously (Suda et al., 1996) . The medium was concentrated 20-fold using an ultra®ltration membrane (Centriprep 10; Amicon), and contained 3610 4 units/ml FasL activity. One unit of FasL activity represents the concentration of FasL that gave half-maximal cytotoxicity against 7.5610 4 W4 cells in 100 ml as described (Tanaka et al., 1995) .
Plasmid construction, and transformation
The expression plasmid for human Bcl-2 (pEF-Bcl2) has been described (Itoh et al., 1993) . The human Jurkat cell line (ATCC TIB152) was maintained in RPMI1640 medium containing 10% fetal calf serum (Life Technologies). Jurkat cells (1610 7 ) were co-transfected by electroporation (Suda et al., 1993) with 50 mg of the expression plasmid and 1 mg of pBSpacDP carrying the puromycin-resistant gene. The puromycin-or hygromycinresistant transformants were selected with 1 mg/ml puromycin. The transformant clones expressing human Bcl-2 were selected by Western blotting analysis using antihuman Bcl-2 antibody. Two independent transformant clones (JB-2 and JB-3) overexpressing human bcl-2 were thus identi®ed.
Assay for cell viability and DNA fragmentation
Cell viability was assayed by using WST-1 methods essentially as described previously (Tanaka et al., 1995) . In brief, cells (5610 4 cells in 100 ml) were stimulated with various concentrations of anti-Fas antibody. Twelve hours later, 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl) 2 [H] tetrazolium monosodium salt (WST-1; Dojin Laboratories, Japan) and 1-methoxy-5-methylphenazinium methylsulfate were added to ®nal concentrations of 5.0 and 0.2 mM, respectively, and incubated for 1 h. Cell viability was determined by measuring the absorbance with a test wavelength of 450 nm and a reference wavelength of 620 nm using an ELISA autoreader. DNA fragmentation in the apoptotic cells was determined as described previously (Enari et al., 1995) .
Flow cytometric analysis and Western blotting
For¯ow cytometry, approximately 1610 6 cells in 100 ml were incubated on ice for 30 min with 2.5 ng/ml of antiFas antibody (CH11) in staining buer (PBS containing 2% FCS and 0.02% NaN 3 ). After washing with staining buer, the cells were stained on ice for 30 min with uorescein isothiocyanate (FITC)-conjugated anti-mouse IgM antibody (200-fold dilution, Becton-Dickinson). Cells were then washed, and analysed using a FACScan (Becton Dickinson). For Western blotting analysis, cells (5610 5 ) were directly lysed by heating at 858C for 30 min in 100 ml of lysis buer (2.5% SDS, 120 mM Tris-HCl [pH 6.8], 200 mM dithiothreitol, 20% glycerol), and mixed with 100 ml of 26 Laemmli's sample buer. Proteins were separated by electrophoresis on 10 ± 20% gradient or 10% polyacrylamide gels in the presence of 0.1% SDS, and transferred to PVDF membranes (Millipore). After blocking with 100% Block Ace (Dainihon Seiyaku, Japan) or PBST-milk (PBS containing 0.1% Tween 20 and 5% non-fat dry milk), the membranes were incubated at 48C overnight with the respective primary antibody in PBST-Block Ace (PBST containing 25% Block Ace) or PBST-milk. After washing three times with PBST, the membranes were incubated with HRP-conjugated antimouse IgG antibody or anti-rabbit IgG antibody in PBSTBlock Ace or PBST-milk at room temperature for 1 h. After washing with PBST, proteins recognized by the antibody were visualized by a chemiluminescence reaction (Renaissance; DuPont NEN).
Immunoprecipitation with anti-caspase 8 antibody
Jurkat and its transformant cells (2.5610 7 /10 ml) were stimulated with 2.4610 4 units of soluble FasL for 5 min. The cells were solubilized by incubation at 48C for 30 min in lysis buer (20 mM Tris-HCl [pH 7.5], 140 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1 mM p-amidinophenyl methanesulfonyl¯uoride hydrochloride [pAPMSF] , 50 mM NaF, 1 mM Na 3 VO 4 , 10 mg/ml leupeptin, 10 mg/ml aprotinin, 10% glycerol). After removing insoluble materials by centrifugation, the lysates were precleared with protein GSepharose by incubation for 1 h at 48C. Samples were then incubated for 2 h at 48C with 2 mg of anti-caspase 8 antibody and protein G-Sepharose. The immunoprecipitate was washed ®ve times with lysis buer and subsequently dissolved in Laemmli's sample buer.
